Market Place
Sourcing Support
A2 Bio Highlights Tmod™ CAR T-Cell Progress at SITC 2024
09 Nov 2024 //
BUSINESS STD
A2 Bio To Present EVEREST-1 Trial Data At SITC Meeting
04 Oct 2024 //
BUSINESSWIRE
A2 Bio Presents CAR-T Programs At ASCO 2024 Annual Meeting
29 May 2024 //
BUSINESSWIRE
A2 Bio Highlights CAR-T Programs at ASCO 2024
24 Apr 2024 //
BUSINESSWIRE
A2 Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530
04 Mar 2024 //
BUSINESSWIRE
A2 Bio Presents Poster Presentations Highlighting BASECAMP-1 and EVEREST-1
02 Nov 2023 //
BUSINESSWIRE
A2 Bio Announces Oral and Poster Presentations at SITC
16 Oct 2023 //
BUSINESSWIRE
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530
30 May 2023 //
BUSINESSWIRE
A2 Bio Identifying Tumor Patients for Inclusion in PI Expected to Begin in 2023
07 Nov 2022 //
BUSINESSWIRE
A2 Bio publishes findings from its highly selective Tmod cell therapy platform
02 Mar 2022 //
PRNEWSWIRE
A2 Bio to Present at ASCO-GI 2022 on Use of NGS to Identify GI Cancer Patients
18 Jan 2022 //
BUSINESSWIRE
A2 Biotherapeutics nabs $71M-plus Series B for selective cell therapy pipeline
07 Oct 2020 //
ENDPTS
A2 Biotherapeutics Closes $71.5M Series B
06 Oct 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.